Clinical Trials Logo

Essential Thrombocythemia clinical trials

View clinical trials related to Essential Thrombocythemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06456346 Not yet recruiting - Clinical trials for Essential Thrombocythemia

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Start date: August 5, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.